Monday, October 3, 2022


Biotechnology News Magazine

AbCellera Granted U.S. Patent Covering its Trianni Mouse® Technology

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

January 19, 2021

AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced it has expanded its intellectual property (IP) portfolio to include its Trianni Mouse® technology.

AbCellera uses the transgenic animal technology to generate fully human monoclonal antibodies for its drug discovery programs with biotech and pharma partners. The United States Patent and Trademark Office (USPTO) issued patent no. 10,881,084 titled “Transgenic Animals and Methods of Use” to Trianni, Inc. (Trianni), an AbCellera Company.

“This patent is an important addition to our IP portfolio, providing protection to our proprietary technology in the U.S.,” said Carl Hansen, Ph.D., CEO of AbCellera and Trianni. “By generating fully human antibodies in the first step of the discovery process, we’re able to increase the speed and efficiency of our partners’ programs to develop therapeutic antibodies.”

Trianni’s genetic engineering technology, which AbCellera acquired in November 2020, is an advanced transgenic platform for developing mice that produce human antibodies. The flagship Trianni Mouse® platform was designed to maximize immune responses, increase antibody diversity, and preserve natural maturation of fully human antibodies. It is also a core platform for quickly developing increasingly powerful transgenic mouse technologies for use in partner programs.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine